Barclays PLC Boosts Stock Position in Perspective Therapeutics, Inc ...

3 days ago · Barclays PLC lifted its position in Perspective Therapeutics, Inc. (NYSE:CATX – Free Report) by 587.9% in the third quarter, Holdings Channel.com reports. The firm owned …

9%
OFF

Barclays PLC Boosts Stock Position In Perspective Therapeutics, Inc ...

2 weeks from now

3 days ago · Barclays PLC lifted its position in Perspective Therapeutics, Inc. (NYSE:CATX – Free Report) by 587.9% in the third quarter, Holdings Channel.com reports. The firm owned …

etfdailynews.com

5%
OFF

Barclays PLC Boosts Position In Structure Therapeutics Inc

2 weeks from now

Dec 23, 2024 · Barclays PLC raised its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 64.5% in the 3rd quarter, according to the company in its most recent filing …

marketbeat.com

7%
OFF

Barclays PLC Boosts Stock Position In Spyre Therapeutics, Inc.

2 weeks from now

Dec 24, 2024 · Barclays PLC grew its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 64.7% in the 3rd quarter, according to its most recent 13F filing with the Securities …

marketbeat.com

$3.19
OFF

Perspective Therapeutics, Inc. (NYSE:CATX) Receives ... - ETF Daily …

2 weeks from now

Dec 28, 2024 · Shares of CATX opened at $3.19 on Wednesday. The stock’s fifty day simple moving average is $6.86 and its 200-day simple moving average is $10.79. Perspective …

etfdailynews.com

66%
OFF

MetLife Investment Management LLC Buys 19,137 Shares Of …

2 weeks from now

Dec 8, 2024 · Finally, Intech Investment Management LLC bought a new stake in Perspective Therapeutics during the third quarter valued at $137,000. 54.66% of the stock is owned by …

etfdailynews.com

5%
OFF

Barclays PLC Boosts Holdings In Dianthus Therapeutics, Inc

2 weeks from now

Dec 30, 2024 · Barclays PLC raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 390.5% in the 3rd quarter, according to its most recent disclosure with the …

marketbeat.com

3%
OFF

Barclays PLC Purchases 301,389 Shares Of Fate Therapeutics, Inc ...

2 weeks from now

Dec 29, 2024 · Barclays PLC lifted its position in Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 245.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 424,277 …

americanbankingnews.com

$1.49
OFF

Barclays PLC Raises Stock Position In Regulus Therapeutics Inc.

2 weeks from now

6 days ago · Regulus Therapeutics Stock Down 1.3 %. RGLS opened at $1.49 on Thursday. The firm has a market cap of $97.60 million, a price-to-earnings ratio of -1.39 and a beta of 1.60. …

etfdailynews.com

1%
OFF

Barclays PLC Boosts Holdings In Viridian Therapeutics, Inc

2 weeks from now

Dec 25, 2024 · Barclays PLC grew its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 113.1% during the 3rd quarter, according to the company …

marketbeat.com

1%
OFF

Barclays PLC Grows Position In Applied Therapeutics, Inc.

2 weeks from now

Dec 28, 2024 · Barclays PLC increased its stake in shares of Applied Therapeutics, Inc. (NASDAQ:APLT – Free Report) by 186.1% in the 3rd quarter, according to its most recent …

defenseworld.net

08%
OFF

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired By …

2 weeks from now

Dec 28, 2024 · Barclays PLC owned 0.08% of Neumora Therapeutics worth $1,708,000 […] Barclays PLC raised its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA – Free Report) …

defenseworld.net

6%
OFF

Barclays PLC Buys 45,797 Shares Of Century Therapeutics, Inc.

2 weeks from now

6 days ago · Barclays PLC grew its stake in Century Therapeutics, Inc. (NASDAQ:IPSC – Free Report) by 283.6% during the third quarter, according to its most recent 13F filing with the …

etfdailynews.com

5%
OFF

Barclays PLC Boosts Stake In Astria Therapeutics, Inc.

2 weeks from now

Dec 31, 2024 · Barclays PLC grew its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report) by 70.5% during the 3rd quarter, according to the company in …

defenseworld.net

6%
OFF

Barclays PLC Boosts Holdings In Protagonist Therapeutics, Inc.

2 weeks from now

Dec 21, 2024 · Barclays PLC boosted its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 223.6% in the 3rd quarter, according to its most recent …

marketbeat.com

7%
OFF

Barclays PLC Boosts Holdings In Compass Minerals International, …

2 weeks from now

Dec 30, 2024 · Barclays PLC increased its holdings in shares of Compass Minerals International, Inc. (NYSE:CMP – Free Report) by 76.7% during the 3rd quarter, according to the company in …

defenseworld.net

4%
OFF

Barclays PLC Increases Stock Holdings In Sight Sciences, Inc.

2 weeks from now

Jan 5, 2025 · Barclays PLC increased its holdings in shares of Sight Sciences, Inc. (NASDAQ:SGHT – Free Report) by 317.4% during the 3rd quarter, according to its most …

etfdailynews.com

0%
OFF

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Bought By …

2 weeks from now

Dec 24, 2024 · Barclays PLC lifted its holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 291.0% in the third quarter, according to the company in its most recent 13F …

marketbeat.com

$116000
OFF

Barclays PLC Has $116,000 Stock Holdings In Gyre Therapeutics, …

2 weeks from now

6 days ago · Shares of GYRE stock opened at $9.62 on Thursday. The stock has a 50-day moving average of $12.20 and a 200-day moving average of $12.65. Gyre Therapeutics, Inc. …

etfdailynews.com

0%
OFF

Barclays PLC Raises Position In Thryv Holdings, Inc. (NASDAQ:THRY)

2 weeks from now

Dec 30, 2024 · Barclays PLC raised its position in shares of Thryv Holdings, Inc. (NASDAQ:THRY – Free Report) by 397.0% during the 3rd quarter, according to the company in its most recent …

defenseworld.net

$55.61
OFF

Barclays Issues Positive Forecast For Williams ... - ETF Daily News

2 weeks from now

3 days ago · Shares of Williams Companies stock opened at $55.61 on Friday. Williams Companies has a fifty-two week low of $32.65 and a fifty-two week high of $60.36. The firm …

etfdailynews.com

FAQs about Barclays PLC Boosts Stock Position in Perspective Therapeutics, Inc ... Coupon?

Does Barclays PLC own Regulus Therapeutics Inc?

Barclays PLC lifted its holdings in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS – Free Report) by 285.2% during the 3rd quarter, Holdings Channel reports. The firm owned 84,477 shares of the biopharmaceutical company’s stock after buying an additional 62,549 shares during the period. ...

How many shares does Barclays PLC own?

The firm owned 50,300 shares of the company’s stock after buying an additional 38,248 shares during the quarter. Barclays PLC’s holdings in Sight Sciences were worth $317,000 as of its most recent filing with the Securities and Exchange Commission. ...

Does Barclays PLC own sight Sciences (sght)?

Barclays PLC increased its holdings in shares of Sight Sciences, Inc. (NASDAQ:SGHT – Free Report) by 317.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 50,300 shares of the company’s stock after buying an additional 38,248 shares during the quarter. ...

How much are Barclays PLC's sght shares worth?

Barclays PLC’s holdings in Sight Sciences were worth $317,000 as of its most recent filing with the Securities and Exchange Commission. A number of other hedge funds have also recently added to or reduced their stakes in SGHT. State Street Corp grew its holdings in Sight Sciences by 17.4% in the 3rd quarter. ...

Who owns perspective Therapeutics (catx)?

Finally, Intech Investment Management LLC bought a new stake in Perspective Therapeutics during the third quarter valued at $137,000. 54.66% of the stock is owned by institutional investors and hedge funds. NYSE CATX opened at $3.76 on Friday. The company has a fifty day simple moving average of $9.75 and a 200 day simple moving average of $11.89. ...

How do I receive news & ratings for perspective Therapeutics?

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. ...